Form 4: Sutro Biopharma CFO Edward Albini Reports Stock Option Grant and RSU Vesting

CFO of Sutro Biopharma, Edward Albini, reports acquisition of stock options and vesting of restricted stock units (RSUs) in a recent SEC filing.

Summary

• Edward Albini, CFO and Secretary of Sutro Biopharma, filed a Form 4 with the SEC on March 7, 2024.
• The filing reports transactions that occurred on March 5, 2024.
• Albini acquired 68,000 stock options with an exercise price of $4.54, vesting monthly starting April 1, 2024, and fully vested by March 1, 2028.
• He also acquired 51,000 RSUs, vesting annually beginning March 1, 2025.
• Additionally, 8,750 RSUs vested, and 3,100 shares were withheld by the issuer to cover income tax obligations.
• Following these transactions, Albini beneficially owns 106,743 shares of common stock, 68,000 stock options, and 51,000 unvested RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and RSUs is a positive sign of incentivizing management, but it also represents potential future dilution for existing shareholders.

Positives

• The grant of stock options and RSUs to the CFO suggests an incentive alignment with the company's long-term performance.
• The vesting schedules encourage continued service and commitment from the CFO.

Future Outlook

The vesting schedules for the stock options and RSUs extend to March 1, 2028, and March 1, 2025, respectively, indicating a long-term incentive structure.

Industry Context

Stock option and RSU grants are common practices in the biopharmaceutical industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices for executives in publicly traded biopharmaceutical companies.
• Vesting schedules, such as monthly or annual vesting, are also typical to ensure long-term commitment.
• Companies like Amgen, Gilead Sciences, and Biogen use similar equity-based compensation strategies.

Stakeholder Impact

• Shareholders may experience potential dilution from the issuance of new shares upon exercise of stock options and vesting of RSUs.
• Employees, particularly the CFO, are incentivized to improve company performance due to the equity-based compensation.

Key Dates